Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
The effects of Trikafta/Kaftrio on people with CF who have mutations other than the most common CF mutation (F508del)
Onset of high blood pressure might be possible after the start of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis.